Post

ARRIWYKS
ARRIWYKS
#ModernaQ3VaccineSales Why YES: mNEXSPIKE COVID + mFLUSIVA flu (1st mRNA flu FDA 50+) approved. Cancer vax Intismeran (MRK) Phase 3 hit. FY +10% rev guide. Cash $8B+ after $950M litigation. Valuation insane: $200 vs $22 low → +580% YTD, +295% 6M, high $254. P/S 41x, P/B 9x, EPS -$7.25, Net -141% margin. Street PT $118 (42% down). 3 Buy/14 Hold/3 Sell. Oct 22 -25% on cancer data leak. Call: 80% EPS BEAT (season + cost cuts) but stock - Sell the beat — needs >$950M + loss <-$0.90 + 2026 raise

Haftungsausschluss: OKX Orbit-Inhalt dient nur zu Informationszwecken. Mehr erfahren

Antworten

Noch keine Kommentare. Schreib die erste Antwort!